Genetically modified pigs having at least one cancer and/or at least one co-morbid condition are provided. Also provided are methods of using the pig and derived tumor cells to screen for therapeutic compounds, medical devices or procedures, and/or combinations thereof. Further provided are methods of producing personalized cancer models, including obtaining a tumor sample from a subject, identifying mutations in the tumor sample, and producing a genetically modified tumor or tumor cell line having the same mutations.

The present invention provides: a novel nucleic acid construct encoding a functional fragment of a Trk family member; and use of the nucleic acid construct. A nucleic acid construct in accordance with an embodiment of the present invention encodes a fusion polypeptide including an intracellular domain of Trk and a membrane localization sequence.

Methods of treating traumatic brain injury (TBI) are provided according to aspects of the present disclosure including: converting reactive astrocytes to functional neurons by providing exogenous neurogenic differentiation 1 (NeuroD1, also called ND1 herein) to at least one reactive astrocyte in a damaged region of a subject's brain, such as the brain of a human subject with a TBI. According to aspects, presence of non-functional neurons and reactive astrocytes in the damaged region of the subject's brain are not primarily due to bleeding and/or ischemia in the damaged region. According to aspects of the present disclosure, the traumatic brain injury causes a period of astrogliosis in the damaged region of the subject's brain, and the exogenous NeuroD1 is provided to reactive astrocytes in the damaged region of the subject's brain during the period of astrogliosis or within four weeks after the period of astrogliosis.

The present invention relates to a use of compounds having TRPV4 inhibitory activity or pharmaceutically acceptable salts thereof, or pharmaceutical compositions containing them for the manufacture of a medicament for preventing or treating a retinal disease accompanied with blood flow disorder or cell disorder. It also relates to a method for preventing or treating the disease, wherein the method comprises administering the compounds or the pharmaceutical compositions containing them to humans or animals. The compounds, the pharmaceutically acceptable salts thereof, or the pharmaceutical compositions containing them may be used in combination with one or more second active agents. The present invention relates to a pharmaceutical composition and a kit containing a compound having TRPV4 inhibitory activity or a pharmaceutically acceptable salt thereof, which is used for preventing or treating the disease. Furthermore, it relates to a marker for diagnosing a disease for which treatment with the compound is useful, and a screening method for drugs in preventing or treating the disease.

The present invention provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint.

A modality for preventing or treating fibrotic diseases by identifying a marker protein for myofibroblasts is provided.

The present invention relates to prophylactic or therapeutic agents for fibrotic diseases, which contain an inhibitor of GPR176 as an active ingredient.

The present invention relates to a method for producing animal models of cerebrovascular disease, comprising ligation of the common carotid artery (CCA) and administration of a nitric oxide (NO) inhibitor, animal models of cerebrovascular disease produced thereby, and a method for producing animals having small individual differences in susceptibility to the onset of cerebrovascular disease by using the same. The method for producing animal models of cerebrovascular disease according to the present invention can overcome the conventional problems of complexity and low yield. Particularly, the production method of the present invention can produce animal models of cerebrovascular disease with a high yield by a simple method. Moreover, the animal models produced by the production method may be used in studies to verify the effectiveness and safety of substances for the diagnosis, prevention or treatment of cerebrovascular disease or methods for treatment of cerebrovascular disease, and make it possible to study genes that cause differences in the level of cerebrovascular disease between the animal models. In addition, it is possible to provide offspring animals having uniform susceptibility to the onset of cerebrovascular disease by mating the animal models having similar susceptibilities to the onset of cerebrovascular disease according to the present invention.

The present invention relates to a system for treating eye diseases, and a method for treating eye diseases using the system.

The invention includes compositions and methods for the treating or preventing endometriosis in a subject in need thereof. In one aspect, the invention relates to compositions and methods for inhibiting microRNA451a.

Compositions for and methods of treating liver injury are provided. Said compositions comprise MG53 or express MG53. Said compositions can be used for treating chronic or acute injured liver tissue and can be administered systemically, locally, or both.